AEterna Zentaris

Closed portfolio with an early-phase archive tilt

According to ClinicalTrials.gov-derived indexes, AEterna Zentaris sits in the top decile of US sponsors by registered trial count (#714 of 15,742 sponsors by registered trial count).

21 total trials none currently recruiting 17 completed early-phase tilt top decile by trial count

AEterna Zentaris: 21 sponsored US clinical trials, none currently recruiting.

AEterna Zentaris sponsors 21 registered US clinical trials on ClinicalTrials.gov, none currently recruiting, and 17 completed. 8 of these trials are in Phase 3-4 (later-stage) and 13 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Benign Prostatic Hypertrophy, with 1 trials.

Top-decile sponsor footprint

AEterna Zentaris ranks in the top decile of sponsors by registered trial count (#714 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.

Trial completion reliability score

F 42/100

17 of 21 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (81.0%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.

Indexed trials (enrollment closed)

21 total, page 1 of 1

COMPLETED Phase 3

A Research Study of How Well Macimorelin Works to Find Out if Children Have a Lack of Growth Hormone and How Safe it is

NCT04786873
COMPLETED Phase 3

Validation of Macimorelin as a Test for Adult Growth Hormone Deficiency

NCT02558829
COMPLETED Phase 3

Zoptarelin Doxorubicin (AEZS 108) as Second Line Therapy for Endometrial Cancer

NCT01767155
TERMINATED Phase 2

Phase 2 Trial of AEZS-108 in Chemotherapy Refractory in Triple Negative Breast Cancer

NCT01698281
COMPLETED Phase 1

A Food Effect and QTc Study of Perifosine in Patients With Advanced Malignancies

NCT01224730
TERMINATED Phase 1

A Phase I/II Trial of AEZS-108 in Urothelial Cancer Patients Who Failed Platinum-chemotherapy

NCT01234519
COMPLETED Phase 3

Perifosine Plus Capecitabine Versus Placebo Plus Capecitabine in Patients With Refractory Advanced Colorectal Cancer

NCT01097018
TERMINATED Phase 3

Assessment of Efficacy and Safety of Perifosine, Bortezomib and Dexamethasone in Multiple Myeloma Patients

NCT01002248
COMPLETED Phase 3

Cetrorelix Pamoate IM Regimens in Patients With Symptomatic Benign Prostatic Hyperplasia (BPH)

NCT00670306
COMPLETED Phase 2

Ph II Study of Perifosine for Patients With Carcinoma of the Kidney

NCT00498966
COMPLETED Phase 3

Investigation of a New, Oral Growth Hormone Secretagogue, AEZS-130 as a Growth Hormone Stimulation Test.

NCT00448747
COMPLETED Phase 2

A Phase II Trial of Perifosine Following Tyrosine Kinase Inhibitor (TKI) - Failure in Patients With Renal Cancer

NCT00448721
TERMINATED Phase 3

Cetrorelix (CET) Pamoate Regimens in Patients With Symptomatic Benign Prostatic Hypertrophy (BPH)

NCT00449150
COMPLETED Phase 1

Phase I Study of Perifosine + Lenalidomide and Dexamethasone for Patients With Multiple Myeloma

NCT00415064
COMPLETED Phase 2

A Phase II Study of Perifosine in Patients With Relapsed/Refractory Waldenström's Macroglobulinemia

NCT00398710
COMPLETED Phase 2

Efficacy of Perifosine Alone and in Combination With Dexamethasone for Patients With Multiple Myeloma

NCT00375791
COMPLETED Phase 2

Placebo-Controlled Study of Perifosine + Single Agent Chemotherapy for Metastatic Cancer Patients

NCT00398879
COMPLETED Phase 1

Phase I Trial of Paclitaxel With Perifosine

NCT00399126
COMPLETED Phase 1

Phase I Trial of Docetaxel With Perifosine

NCT00399087
COMPLETED Phase 1

A Phase 1/2 Trial of Perifosine in the Treatment of Non-Small Cell Lung Cancer

NCT00399789
COMPLETED Phase 1

Phase I Perifosine and Gemcitabine Study

NCT00398697

Phase Distribution

PhaseTrial count
Phase 1 7
Phase 2 6
Phase 3 8

Therapeutic Areas

Benign Prostatic Hypertrophy 1
Multiple Myeloma 1
Endometrial Cancer 1
Cancer 1

How the AEterna Zentaris early-phase archive is shaped

21 indexed studies, none listed as recruiting (0% open); 17 completed (81%).

Phase mix: 8 late (III/IV) vs 13 early (I/II) (early-phase heavy).

Top condition: Benign Prostatic Hypertrophy (1 trial), 3 others listed.

How to read a closed sponsor archive

When recruiting_count is zero, the indexed set is completed or otherwise not open. Phase tilt still describes where archived studies sat on the investigational pathway. Re-check ClinicalTrials.gov before acting.

AEterna Zentaris: archived-pipeline peers nationwide

Peers matched on 21 indexed studies with no current recruiting: volume and archive shape, not condition overlap.

AEterna Zentaris sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot). 2×2 strategic matrix plotting 9 entities by Total trials (X) and Recruiting share (Y), with a crosshair dividing the plot into four quadrants. Higher volume & more openFocused & more openHigher volume, mostly closedSmaller & mostly closed 0510152025 0%5%10%15%20% Total trials Recruiting share AEterna ZentarisAmphastar PharmaceuticalsApellis PharmaceuticalsArray Biopharma, now a wholly owned subsidiary of PfizerBasilea Pharmaceutica10xBio22nd Century Group23andMe3-C Institute for Social Development
AEterna Zentaris sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot).

AEterna Zentaris sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.

Sponsors near 21 archived trials

Sponsors with similar archive density (± trial count)

Related

Read our methodology - how this data is sourced, computed, and verified.

What to do with this AEterna Zentaris page

21 registered trials is a research-attention snapshot, not an endorsement of AEterna Zentaris or any single study.

  • None of AEterna Zentaris's trials are currently recruiting in this registry; that can change as new trials post, or check the broader research index. Browse research indexes
  • Benign Prostatic Hypertrophy is the condition AEterna Zentaris studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Benign Prostatic Hypertrophy trials
  • Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. AEterna Zentaris pipeline card: 21 registered trials from official public datasets. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.